Abstract Number: 2951 • 2017 ACR/ARHP Annual Meeting
Responsiveness of the Patient Reported Outcomes Measurement Information System to Golimumab Intravenous and Infliximab Treatment in a Real World Clinical Trial in Rheumatoid Arthritis Patients
Background/Purpose: The Patient (Pt) Reported Outcomes Measurement Information System (PROMIS [P]) questionnaires developed by the NIH have been validated and are a feasible assessment tool…Abstract Number: 1408 • 2016 ACR/ARHP Annual Meeting
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Patient Reported Outcomes Among Patients with Rheumatoid Arthritis: Passion Study
Background/Purpose: Patient (pt) Support Program (PSP) is offered to pts who are prescribed adalimumab (ADA) for their Rheumatoid arthritis (RA). How participation in a PSP…Abstract Number: 2254 • 2016 ACR/ARHP Annual Meeting
Patient Adherence with Biologic Therapy in Rheumatoid Arthritis: A Real-World Review of Compliance
Background/Purpose: Biologic agents (bDMARDs) have been shown to help control disease progression in rheumatoid arthritis (RA) and reduce joint damage. The aim of our research…Abstract Number: 2474 • 2016 ACR/ARHP Annual Meeting
Patients’ Experiences of Using a Smartphone App for Remote Monitoring of Rheumatoid Arthritis, Integrated into the Electronic Medical Record, and Its Impact on Consultations
Background/Purpose: Treatment of patients with rheumatoid arthritis (RA) is guided by monitoring changes in disease severity. At present, patients do not routinely record disease severity…Abstract Number: 2475 • 2016 ACR/ARHP Annual Meeting
Identifying Key Variables for Inclusion in a Smartphone App to Support Clinical Care and Research in Patients with Rheumatoid Arthritis
Background/Purpose: Treatment for patients with rheumatoid arthritis (RA) is shaped by monitoring changes in disease severity over time. At present, clinicians managing RA have few…Abstract Number: 3083 • 2016 ACR/ARHP Annual Meeting
Utility of Patient-Reported Outcomes Measurement Information System (PROMIS) 29 Short Form for Understanding Interplay Between Patient-Reported Outcome Measures and Physician Driven Disease Activity Measures
Background/Purpose: Discordance between patient and physician assessment of rheumatoid arthritis (RA) disease activity strongly associates with pain scores. Patient-reported outcomes measurement information system (PROMIS) 29…Abstract Number: 8 • 2016 ACR/ARHP Annual Meeting
What Factors Relate to Patients Contributing Longitudinal Data Using Smartphone Technology? Findings from RA Patients Participating in Arthritispower Registry
Background/Purpose: Data capture of patient reported outcomes (PROs) is gradually shifting from data collection on paper in medical office to use of computer or mobile…Abstract Number: 16 • 2016 ACR/ARHP Annual Meeting
Differences Between Patient and Physician Global Assessment on Rheumatoid Arthritis Disease Activity Status in High and Lower Income Countries Contribute to Inequity
Background/Purpose: Rheumatoid arthritis (RA) patients score their global disease activity (ptGD) on average higher than physicians (phGD). This difference can vary between countries with high…Abstract Number: 84 • 2016 ACR/ARHP Annual Meeting
Treatment Outcomes and Predictors of Patient Support Program Use Among Patients with Rheumatoid Arthritis: Results from a Post-Marketing Observational Study (PMOS)
Background/Purpose: Patient (pt) support programs (PSPs) are offered to Rheumatoid arthritis (RA) pts to help manage treatment of this chronic disease. Little information is available…Abstract Number: 522 • 2016 ACR/ARHP Annual Meeting
Patient-Provider Discordance in Global Assessments of Disease Activity in Patients with Rheumatoid Arthritis: Persistence, Predictors and Impact
Background/Purpose: Patient-provider discordance in global assessment (GA) of disease activity is a potential threat to patient-centered management of individuals with RA. The estimated prevalence of…Abstract Number: 540 • 2016 ACR/ARHP Annual Meeting
The Importance of Outcome Measures in Rheumatoid Arthritis – Validity of the Routine Assessment of Patient Index Data 3 in a Real World Setting
The Importance of Outcome Measures in Rheumatoid Arthritis - Validity of the RAPID3 (Routine Assessment of Patient Index Data 3) in a United States “Real…Abstract Number: 559 • 2016 ACR/ARHP Annual Meeting
Comparison of Multi-Dimensional Health Assessment Questionnaire (MD-HAQ)-Based and Patient-Reported Outcomes Measurement Information System (PROMIS) 29-Based Routine Assessment of Patient Index 3 (RAPID3) for Assessing Rheumatoid Arthritis Disease Activity
Background/Purpose: Patient-reported outcomes measurement information system (PROMIS) 29 is recommended by the National Institute of Health (NIH) consensus panel as the preferred battery of…Abstract Number: 147 • 2015 ACR/ARHP Annual Meeting
Fatigue, Coping, Sleeping Disorders and Productivity Were Still Not Frequently Reported in Rheumatoid Arthritis Trials Published in 2014-2015: A Systematic Literature Review
Background/Purpose: In a systematic literature review (SLR), frequency of patients reported outcomes (PROs) related with rheumatoid arthritis (RA) was evaluated between 2005 and 2007 (1).…Abstract Number: 505 • 2015 ACR/ARHP Annual Meeting
Comparative Effectiveness and Time to Response Among Abatacept, Adalimumab, Certolizumab, Etanercept, Infliximab, Rituximab and Tocilizumab in a Real World Routine Care Registry
Background/Purpose: With the availability of multiple biologic agents, each with different modes of action, use of real world registries provide the manner in which to…Abstract Number: 1308 • 2015 ACR/ARHP Annual Meeting
MRI Measures of Disease Activity and Joint Damage Are Associated with Patient-Reported Outcomes in Rheumatoid Arthritis
Background/Purpose: We used data from a large clinical trial of golimumab (GO-BEFORE) to comprehensively assess associations between magnetic resonance imaging (MRI) measures of synovitis, osteitis,…
ACR Meeting Abstracts